Collaborations

Research agreement signed with Defence R&D Canada for development of influenza drug

Published in Vaccine Weekly, December 28th, 2005

Hemispherx Biopharma, Inc., (HEB) announced that they have entered into an agreement with Defence R&D Canada - Suffield (DRDC), an agency of the Canadian Department of National Defence, to evaluate the antiviral efficacy of its experimental therapeutic Ampligen and Alferon for protection against human respiratory influenza virus infection in well validated animal models.

DRDC Suffield is conducting research and development of new drugs that could potentially become part of the arsenal of existing antiviral weapons to combat the Avian flu. The initial study will focus on the testing of potential drugs against the respiratory influenza virus infection on a mouse-adapted...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-12-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry